Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK105550)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL136664)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 C217987)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM007347)
Article History
Received: 15 December 2021
Accepted: 19 December 2021
First Online: 17 January 2022
Competing interests
: JCR is a founder, scientific advisory board member, and stockholder of Sitryx Therapeutics, a scientific advisory board member and stockholder of Caribou Biosciences, a member of the scientific advisory board of Nirogy Therapeutics, has consulted for Merck, Pfizer, and Mitobridge within the past 3 years, and has received research support from Incyte Corp., Calithera Biosciences, and Tempest Therapeutics.